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ABSTRACT
The PubChem BioAssay database (http://pubchem
.ncbi.nlm.nih.gov) is a public repository for biologi-
cal activities of small molecules and small
interfering RNAs (siRNAs) hosted by the US
National Institutes of Health (NIH). It archives exper-
imental descriptions of assays and biological test
results and makes the information freely accessible
to the public. A PubChem BioAssay data entry
includes an assay description, a summary and
detailed test results. Each assay record is linked to
the molecular target, whenever possible, and is
cross-referenced to other National Center for
Biotechnology Information (NCBI) database
records. ‘Related BioAssays’ are identified by
examining the assay target relationship and
activity profile of commonly tested compounds.
A key goal of PubChem BioAssay is to make the
biological activity information easily accessible
through the NCBI information retrieval system-
Entrez, and various web-based PubChem services.
An integrated suite of data analysis tools are avail-
able to optimize the utility of the chemical structure
and biological activity information within PubChem,
enabling researchers to aggregate, compare and
analyze biological test results contributed by
multiple organizations. In this work, we describe
the PubChem BioAssay database, including data
model, bioassay deposition and utilities that
PubChem provides for searching, downloading and
analyzing the biological activity information
contained therein.
INTRODUCTION
PubChem (http://pubchem.ncbi.nlm.nih.gov) (1,2)
(Figure 1) is an open public repository containing
chemical structures and biological properties of mole-
cules including small molecules and siRNA reagents.
This resource, ﬁrst available in September 2004, is
part of the US National Institutes of Health (NIH)
Molecular Libraries Roadmap Initiative. This research
program aims to identify and develop chemical probes
through high-throughput screening of small molecules
that modulate the activity of gene products (4,5) and to
accelerate chemical biology research and facilitate drug
development by oﬀering biomedical researchers access to
the large-scale screening capacity and the biological test
results generated via PubChem.
PubChem consists of three interconnected databases:
Substance, BioAssay and Compound. The Substance
database (primary accession—SID) contains contributed
sample descriptions (primarily small molecules) provided
by depositors. The BioAssay database (primary acces-
sion—AID) contains contributed assay descriptions
and associated biological screening results of substances
provided by depositors. The Compound database
(primary accession—CID) contains the unique chemical
structures derived from the Substance database records,
thus allowing substance information (e.g. bioassay data)
from diﬀerent depositors to be viewed for unique chemical
structures. The PubChem BioAssay system is the reposi-
tory of the small molecule screening data generated by the
Molecular Library Screening Center Network (MLSCN)
and the Molecular Library Probe Production Center
Network (MLPCN) under the NIH Molecular Libraries
Program (MLP) (6,7). PubChem also receives biological
property contributions from many other organizations.
Biological test results contained in the PubChem
BioAssay database consist of information generated
through high-throughput screening experiments, biologi-
cal and medicinal chemistry research, as well as those
extracted from the literature. PubChem BioAssay
currently contains over 1700 biochemical and cell-based
bioassay screens, containing nearly 60million biological
activity outcomes for several thousand diﬀerent pro-
tein and gene targets. These test results provide biological
annotations for more than 750000 unique small molecule
chemical structures and tens of thousands of siRNA
probes. While the majority of the archived test results
were deposited by MLP screening centers, PubChem
BioAssay contains biological test results contributed by
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programs at various academic institutions and individual
research laboratories. This includes, for example, human
tumor cell line screening data from the Developmental
Therapeutic Program (DTP) (8,9) at the US National
Cancer Institute (NCI), toxicology data from the
DSSTox (10) program at the US Environmental
Protection Agency (EPA), biological test results from
the US National Institute of Neurological Disorders and
Stroke (NINDS) Approved Drug Screening Program and
the US National Institute of Mental Health (NIMH)
Psychoactive Drug Screening Program (PDSP), as well
as anticonvulsant data from NINDS. It also includes
ligand–protein binding activity data generated by the
targeted high-throughput structural biology experiments
at the European Structural Genomics Consortium (11),
literature-extracted bioactivity data from the BindingDB
(12) project, the IUPHAR (13) project and the PDBBind
(14) project, high-throughput screening results from
ChemBank (15), and target proﬁling and phenotypic
assays from commercial vendors (16). A new addition to
PubChem BioAssay database is biological activity data
for siRNA probe reagents. The siRNA screening results
currently contained in PubChem BioAssay include
high-throughput siRNA screening data contributed by
the RNAi Global Initiative (http://www.rnaiglobal.org/),
data extracted from the literature by the NCBI Probe
resource (http://www.ncbi.nlm.nih.gov/probe) as well as
a recent contribution from authors of the journal ‘Cell’
reporting research results on the identiﬁcation of clock
genes and modiﬁers (17).
With substantial growth in data volume and diversity,
and increasing demand from public users, PubChem faces
great challenges comparing to many other chemical
biology resources. Collecting, archiving and organizing
each individual biological test, as well as bioassay infor-
mation across multiple screening experiments and across
multiple types of reagents (i.e. small molecules versus
siRNAs), complement data quantity with diversity and
breadth of coverage of available information. Providing
eﬀective means to store, retrieve and analyze tens
of millions of bioassay outcomes across thousands of
bioassays is a considerable task. Developing a robust
information-tracking system, providing a user-friendly
data deposition interface as well as data analysis tools
for public usage all add to the complexity of the eﬀort.
Such systems and services, by necessity, must be intuitive
to use while still providing advanced search features to
help researchers ﬁnd relevant information and make the
scientiﬁc connections that transform data into knowledge.
PubChem BioAssay accomplishes this by encouraging
chemical biology researchers to share their scientiﬁc
Figure 1. PubChem home page. One can search PubChem Substance, Compound and BioAssay by entering the search term into the input box or
access the summary, chemical structure search and bioactivity analysis service using the respective links.
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resource, by integrating with the rich database resources
and information retrieval system at NCBI. Such database
integration provides scientists a series of integrated tools
and services to analyze biological test results and to
extract those biologically interesting molecules and
chemical probes contained within PubChem.
PUBCHEM BIOASSAY DATA MODEL
The PubChem BioAssay model is designed to allow
unambiguous representation of data produced by
various experimental procedures, to support the retrieval
of individual information components and to track the
biological target and the respective bioactivity outcome.
An assay record, represented by a unique PubChem
BioAssay accession AID, is organized in two parts, the
assay description and the assay results. The assay descrip-
tion includes a name, data source, purpose, experimental
protocol, tested reagent category (e.g. small molecule
versus siRNA), comment and result/readout descriptions.
The PubChem BioAssay archive format provides
numerous ways for contributing organizations to
annotate a given assay. These annotations include:
textual descriptions; target information, including cross-
references to GenBank (18) records, name, description,
molecule type (e.g. protein versus nucleotide) and
taxonomy; qualiﬁed cross-references to PubMed citations,
three-dimensional protein structures, biosystems and
diseases; and URLs back to the depositor’s website.
Each BioAssay record can contain as many comments
and as much descriptive text as needed to provide the
overall background of the assay, such as the biological
system tested in the assay or the relationship between a
disease and the selected therapeutic target. The assay
protocol, similar to the method section of a journal
publication, helps to explain the actual methodology of
the assay.
Multiple test result ﬁelds may be speciﬁed per assay,
each with a unique test identiﬁer (TID), name, description,
data type, data unit and annotation for cross-references.
The PubChem assigned TID indicates a particular test
result or readout when reporting results for a given
substance. The number of test readouts are only limited
by their potential usability.
Many biological assays employ a dose–response
scheme, with a primary endpoint [e.g. IC50 (http://en
.wikipedia.org/wiki/IC50)]. PubChem requires this key
readout, denoted as an ‘active concentration summary’,
to have micro-molar units and requires the experimental
concentrations for the corresponding dose–response
readouts (also in micro-molar concentration and referred
to as ‘tested concentrations’) to be designated on the
respective test result ﬁelds as an attribution. These special-
ized readouts allow PubChem users to classify and rank
hits of a screening test and search bioassay results with
speciﬁc values or ranges of primary outcomes.
Biological screening data submitted to PubChem are
diverse and assay speciﬁc. As such, there are no speciﬁc
requirements on the presence of particular test readouts;
however, PubChem requires a summary result for each
tested chemical sample. The summary result is 2-fold:
bioactivity outcome and bioactivity score. The ‘bioactivity
outcome’ partitions results and includes ﬁve categories:
chemical probe, active, inactive, inconclusive and
unspeciﬁed. Criteria and rationale used by the testing
organization for summary results, as well as description
about possible factors of artifact, are often provided in the
assay comment section, aiding the user’s interpretation
and utilization of the biological data.
The assay result section includes the results for all tested
substances. Results reported per substance can include
both assay readout and annotations, including target
description, comment on the individual biological test
result, cross-links to other NCBI resources and URLs to
the depositor’s website. Assay data are provided in a
tabular format, with one tested substance per row and
one assay test readout or annotation per column.
A substance need not have results reported for all
deﬁned test readouts. There is no limit on the count of
substance test results in an assay record.
The stage of the biological experiments in PubChem
varies. Each assay is classiﬁed by the contributing organi-
zation according to the stage of the assay project,
which is described as the ‘activity outcome method’ in
PubChem. These methods include: ‘screening’ assay,
usually a primary high-throughput assay where the
activity outcome is based on percentage inhibition from
a single dose; ‘conﬁrmatory’ assay, typically a low-
throughput assay where the activity outcome is based on
a dose–response relationship with multiple tested
concentrations; ‘summary’ assay, for validated chemical
probes or small molecule leads, summarizing information
from multiple assays; and ‘other’, those assays that do not
ﬁt the previous categories. For MLPCN projects, a
summary assay is required for each biological screening
project to describe the identiﬁed chemical probes, report
screening steps that lead to the project progress and com-
municate the bottom line of the screening campaign to
the scientiﬁc community. A summary assay, therefore,
consists of a list of veriﬁed chemical probes if identiﬁed,
a comprehensive text description of the screening
campaign and links from this summary assay AID to all
associated screening assays deposited in PubChem, to the
targeted genes and proteins in GenBank and to the scien-
tiﬁc publications describing the screening experiments
available in PubMed. To make it easier for the MLP
screening centers to create and update summary assays,
the PubChem deposition system allows one to create a
simple summary template at an early stage and to
update the summary assay with any new information
and experimental results as the screening project
progresses.
It is essential to specify and track the information of the
assay target and precisely group and annotate the biolog-
ical tests based on the respective molecular target.
PubChem BioAssay provides several models to do so.
The traditional assay model allows for the speciﬁcation
of a single target for the entire assay record, along
with associated annotations such as links to the respective
gene, taxonomy and biological pathway information.
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entire assay dataset are solely for the speciﬁc target, for
example, to describe the biological eﬀect of the small
molecules on the functionality of one enzyme.
PubChem also supports the presentation and annota-
tion of multiple highly related bioactivity outcomes, such
as a proﬁling assay against a panel of molecular targets,
in a single assay. Such a panel-type PubChem BioAssay
record can contain multiple test readouts and respective
bioactivity outcome annotations for each individual
target, as well as for an individual cell line or species
deﬁned within the ‘panel’. Each of such targets, cell lines
or species is regarded as a ‘panel component’ in the data
model and a unique panel component identiﬁer (PID) is
assigned to each. Description of the experiments,
including a component name, general goal, speciﬁc exper-
imental protocol and information of assay target, can be
provided for each individual panel component. The test
results for an individual panel component, which may be
multiple, can be designated as a ‘bioactivity outcome’ or
‘active concentration’, if necessary, or otherwise treated as
regular readouts.
Panel assay results are complex. This expansion of
the PubChem BioAssay data model allows for the descrip-
tion of a compound proﬁling screening test and enables
PubChem to record and annotate multiple related
bioactivity outcomes under a single AID, which helps
facilitate comparison and evaluation of compound
bioactivities using the PubChem data analysis proﬁling
tools. To see a panel assay example, one may examine
the kinase-proﬁling assay for AID 1433 (http://pubchem
.ncbi.nlm.nih.gov/assay/assay.cgi?aid=1433).
A third bioassay data model allows one to specify a
speciﬁc target for each individual tested sample. In this
case, a speciﬁc test result is deﬁned as containing the
assay target. For example, one test result deﬁnition may
be deﬁned as containing the target identiﬁer, a GenBank
Protein GI number, while another test result deﬁnition
may be deﬁned as containing a short name of the target.
This model was introduced originally to support the
accommodation of siRNA screening results, where an
entire genome may be screened with tens of thousands
of siRNA reagents designed for thousands of gene
targets of the genome, with one or several siRNA
reagents corresponding to each of the targeted genes.
Thus, in this situation, the nucleotide or gene target anno-
tation needs to be siRNA speciﬁc, and associated with
each tested sample. To see an example, one may look at
AID 1622, a viability screen of human kinase and cell
cycle genes (http://pubchem.ncbi.nlm.nih.gov/assay/
assay.cgi?aid=1622). This data model can also be
employed to encode bioactivity information for multiple
targets where substance data points across targets are
sparsely populated, such as the data contributed by
PDBbind in AID 1811 (http://pubchem.ncbi.nlm.nih
.gov/assay/assay.cgi?aid=1811).
In all, the PubChem BioAssay data model supports a
comprehensive description of screening experiments and
test results by providing ﬂexible schemes to encode
bioassay information. Such schemes facilitate public user
discovery; for example, the ‘bioactivity score’ provides the
relative activity rank to enable more interesting results to
be shown ﬁrst, while the provision of the bioactivity
outcome summary to provide a shortcut from each assay
to a list of ‘hits’ discovered in each screen, empowers the
PubChem user to rapidly identify and partition biological
assay results of interest. More importantly, the required
standard bioassay metrics and annotation of assay targets
allow PubChem to provide powerful tools for users to
promptly classify and compare results across disparate
assays and targets for a given set of chemical samples.
PUBCHEM BIOASSAY DATA SPECIFICATION,
DATABASE STRUCTURE AND UPDATE TRACKING
The hierarchical data in the PubChem BioAssay archive
are encoded in the data structure ASN.1 notation.
All information about a single assay can be contained
in a single ASN.1 or equivalent XML data object.
It provides separate tagged ﬁelds for each aspect of the
assay as detailed in the available speciﬁcation in ASN.1
and XML Schema formats, respectively:
ftp://ftp.ncbi.nlm.nih.gov/pubchem/speciﬁcations/pubchem.asn
ftp://ftp.ncbi.nlm.nih.gov/pubchem/speciﬁcations/pubchem.xsd
PubChem assay records are stored in a relational data-
base using Microsoft SQL server. The database architec-
ture is designed for eﬃcient storage, tracking and fast
retrieval of large-scale biological test results. Test results
are keyed on a unique combination of three identiﬁers:
AID, SID and TID. Assay data are partitioned into
multiple ‘de-normalized’ database tables for rapid search
and retrieval. Certain summary information, such as
tested substances count, unique chemical structures
count and TID numerical range are pre-computed to
further facilitate eﬃcient retrieval through the data
analysis tools.
PubChem allows all aspects of a bioassay to be revised.
Updates to a bioassay textual description or annotation
are considered to be a ‘minor change’ and recorded as a
description revision. Updates to a substance result are
tracked by increasing the ‘test result’ version, with both
duplicate tests and revision to an existing test being con-
sidered as test result updates. Major revision to a bioassay
is allowed, which includes changes such as addition or
removal of test result ﬁelds. All bioassay test results
must be restated by the data depositor upon such funda-
mental changes. Whenever a major version is incremented,
the description revision and test result version are reset to
‘1’. Only the current version of description and corre-
sponding test results are shown in the PubChem display
system. However, all revisions are archived, tracked and
retrievable.
BIOASSAY DEPOSITION AND UPDATE
PubChem is an open repository and any organization may
contribute data. The only caveat is that contributed infor-
mation must be real (e.g. the substance data must exist
and the primary assay data experimentally derived) and
not theoretical or virtual in nature. To deposit data, one
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(http://pubchem.ncbi.nlm.nih.gov/deposit/) and ﬁll out
the web form for a PubChem deposition account. When
applying for a deposition account, one needs to provide a
valid contact address, bonaﬁde organization information
and specify a name for the data source, which is the data
attribution describing the resource to which all future
depositions will be referred. Furthermore, one must
agree to and is bound by the ‘PubChem Data Transfer
Agreement’ (http://pubchem.ncbi.nlm.nih.gov/deposit/
dta.html), where the depositor retains rights to their
data but gives PubChem the ability to display and redis-
tribute provided information. A hold-until date may also
be speciﬁed for an assay submission. This may be desirable
for journal-article authors, for example, to make auxiliary
data in PubChem available as of the publication date of
the article. If a hold-until date is speciﬁed, the deposited
assay record will be uploaded immediately but the data
content is made available for search and public access only
upon that date.
It is straightforward to deposit data. To submit a
biological assay, an appropriate description must be
provided. These may be conveniently entered using the
webforms in the PubChem Deposition Gateway. Assay
test results for substances may be uploaded using
a comma-separated value (CSV) formatted ﬁle. The
uploaded data resemble a data table, with each column
in the CSV ﬁle corresponding to a particular test result
and each row representing all of the test results for a single
substance record. Prior to submission of assay results, a
description of the substances tested in an assay must be
provided and publicly available in PubChem. Substance
deposition can be made using the industry standard SD
format (http://www.symyx.com/downloads/public/ctﬁle/
ctﬁle.jsp). The SD ﬁle should contain predeﬁned
PubChem SD ﬁelds to be accepted by the PubChem depo-
sition system. The only requirement is that each substance
in the SD ﬁle must have a unique registry ID. In addition
to web-based submission, XML-based submissions and
automated FTP data transfers are also possible. Trained
staﬀ is available to assist and detailed instruction for
depositing data into PubChem is available (http://
pubchem.ncbi.nlm.nih.gov/deposit/deposit_help.html).
Upon data submission, automated data validation
is performed to ensure that the submitted assay data
follows the data type description of the readout, for
example. Contributing organizations may preview assay
description and data presented by PubChem assay
summary service prior to commit their data to be loaded
into PubChem, whereby PubChem staﬀ perform a ﬁnal
check of the data submission and approve the deposition
for release into PubChem. If not an update, an AID is
assigned at load time and a ﬁnal notiﬁcation is sent to
the depositor after contributed data are publicly available.
All updates on PubChem BioAssay records, including
minor changes, major revisions and test result additions,
may be done through the deposition interface or using
the FTP data transfer scheme. Individual test results as
well as an entire assay record can be revoked. Similarly,
a PubChem substance record can be revoked, though all
associated assay results must be revoked ﬁrst. Assay
version, description version or test result version may
change depending on the update type, but the assay
AID remains the same.
It should be noted that biological test results refer to
substances deposited by the same contributor to associate
test results with the physical samples tested. Assay data
may also refer to substances deposited by another con-
tributor, but only when the latter is designated as a
collaborating sample provider. In such collaborations,
the substance depositor must agree to associate unique
substance identiﬁers (SIDs) with the physical samples
provided to any assay depositor. The NIH Molecular
Libraries Program (MLP) organizes one such collabora-
tion, under which the NIH Molecular Libraries Small
Molecule Repository (MLSMR) associates new
PubChem SIDs with any newly purchased, newly synth-
esized or newly puriﬁed physical sample. Each MLP
screening center can test substance samples in this collec-
tion and refer to MLSMR substance descriptions when
depositing screening results in PubChem.
INTEGRATION WITH PUBCHEM SUBSTANCE,
COMPOUND, TARGET AND OTHER NCBI
DATABASES
Each assay record is linked to all tested substances.
A substance is in turn linked, whenever possible, to a cor-
responding compound. Separate links are created from
each assay to subsets of chemical probes, active and
inactive substances and compounds. Similarly, substances
and compounds are linked to the bioassays where they are
tested, as well as to the subsets of bioassays where they
are chemical probes, active or inactive. These shortcuts
allow one to rapidly retrieve a list of active substances
or compounds directly using the Entrez search system
(http://www.ncbi.nlm.nih.gov/sites/gquery), the text-
based global interface for searching all NCBI databases
(3). For example, to ﬁnd out how many substances are
considered active in a pair of assays with related protein
targets, one could retrieve the list of active substances for
each assay and then ﬁnd the intersection of the lists by
performing a Boolean ‘AND’ operation in the Entrez
history facility. Alternatively, one can ﬁnd out the subset
of substance records that are active in a primary screening
assay but inactive in a corresponding conﬁrmatory assay.
Navigating bioassay results in the same manner using
compound records to aggregate on depositor substance
descriptions creates a broader range of bioactivity proﬁle
available for the same chemical structure.
Assay target information allows PubChem to provide
specialized data analysis tools and interfaces to navigate
bioactivity results across protein targets, to examine
compound selectivity, to identify oﬀ-target eﬀects and to
ﬁlter out promiscuous compounds. To date, more
than half of all PubChem BioAssay records contain a
discrete molecular target with a link to the corresponding
GenBank protein and nucleotide records. Assay
targets are further annotated with the NCBI BioSystems
(http://www.ncbi.nlm.nih.gov/biosystems) biological
pathway information, helping to facilitate understanding
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for the eﬀect of bioactive compounds. Additionally,
protein targets are linked to the curated NCBI
Conserved Domain Database (CDD) (19) (http://www.
ncbi.nlm.nih.gov/cdd) and to three-dimensional structures
of closely related proteins contained in the NCBI
Molecular Modeling Database (MMDB) (20)
(http://www.ncbi.nlm.nih.gov/structure). Such links help
to identify conserved active sites in proteins and
protein–ligand interactions.
Searching PubChem BioAssay targets via the NCBI
BLAST service (21,22) (http://blast.ncbi.nlm.nih.gov)
provides an additional way for a molecular biologist to
discover chemical probes or eﬀective siRNA reagents
contained in PubChem. Sequences of assay targets are
used to construct a BLAST database for a protein simi-
larity search. The BLAST service now highlights assay
targets among the hits when reporting search results.
Each of such BLAST hits is linked back to the associated
assay records in PubChem, thus facilitating, for example,
the discovery of bioactive compounds, including the
highly potent and selective chemical probes identiﬁed for
a speciﬁc target.
RELATED BIOASSAYS
For a public repository with biological test results
contributed by many organizations, assays can be
related in a number of ways. For example, diﬀerent
laboratories may submit assays that screen for inhibitors
of the same protein target. The same laboratory may also
provide diﬀerent assay records for the same target, e.g.
one for primary screening data and others reporting
follow-up experiments. Given the breadth of tested
targets per compound and compounds tested per target,
PubChem provides the means to readily identify such
assay relationships and suggests a focus for subsequent
data mining.
Three computationally derived methodologies are
provided for deriving inter-assay relationships in
PubChem BioAssay: ‘Related BioAssays by Activity
Overlap’, ‘Related BioAssays by Protein Target
Similarity’ and ‘Related BioAssays by BioSystems via
Protein (or Gene) Target’. In the method ‘Related
BioAssays by Activity Overlap’, one assay is considered
related to another if there is at least one chemical structure
active in both assays. Assays neighbored using this
method are ordered according to the similarities of
their activity proﬁles. Such methodology does not
allow direct conclusions to be made on the relationship
between assays; however, it may allow one to rapidly
identify, and thereby avoid, promiscuous inhibitors,
or to help discover more complex target-based
relationships.
In the method ‘Related BioAssays by Protein Target
Similarity’, related bioassays are identiﬁed by checking
sequence similarity signiﬁcance between protein targets.
To this end, all unique assay target protein sequences in
PubChem are compared to each other by performing a
BLAST search, using an E-value threshold of 0.01 as the
cutoﬀ for pertinent similarity. This neighboring basis is
useful to identify bioassays screening similar targets and
allows one: to group compounds tested against the same
or related targets; to isolate chemical agents with distinct
biological eﬀects, such as agonists and antagonists; to
compile a list of inhibitors identiﬁed in diﬀerent bioassays;
and more.
In the method ‘Related BioAssays by BioSystems via
Protein (or Gene) Target’, common biological pathways
of the respective targets are examined. Related bioassays
are identiﬁed when the protein or gene targets are involved
in the same biological pathway found within the NCBI
BioSystems database. Such a relationship allows users to
utilize this neighboring relationship to aggregate assay
results and identify compounds aﬀecting a common
pathway. This type of neighboring relationship can act
as a bridge between small molecule screens against
a discrete protein target or between interfering
siRNA gene expression knockout experiments involved
in the same pathway for disease-oriented therapeutic
research.
Independent of computed bioassay neighboring,
‘Related BioAssays’ may be speciﬁed by the assay depos-
itor. Normally, these relationships are provided when
further conﬁrmatory or counter-screenings are performed,
thus providing the means to rapidly identify all screens
involved in the same screening campaign. Typically, a
‘Summary’ assay is deﬁned within such a grouping that
provides an overview of how each assay is involved in the
overall eﬀort and recaps the ﬁndings.
The ‘Related BioAssays Summary’ tool, accessible
from the BioAssay Summary service for an assay record,
allows one to examine or to select one of the pre-
computed or depositor-speciﬁed assay–assay relation-
ships. Interestingly, there is often clear overlap between
the respective related bioassays identiﬁed by activity
overlap and by sharing protein target similarity. One
bioassay example to better understand the neighboring
relationships in PubChem was contributed by the NIH
Chemical Genomics Center (NCGC), AID 1751
(http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=
1751), which looks for inhibitors and activators of human
muscle isoform 2 pyruvate kinase. Examination of the
neighboring relationships for protein target by selecting
the ‘Target Similarity’ tab (Figure 2a) indicates that
there are several assay records containing the same
targets (AIDs 1540, 1631 and 1634). In addition, two
sets (AIDs 954, 958, 1542 and 1780; AIDs 1541, 1543,
1781, 1782) have high sequence identities: 96% and
72%, respectively. Several of these assays (AIDs 1504,
1631, 1541, 1543 and 1782) are also found among the
neighbor lists when examining the related assays based
on the ‘Related BioAssays by Activity Overlap’ method
due to two commonly tested and commonly active
compounds (with CIDs 650361 and 654375, respectively).
These homologous pyruvate kinases with high sequence
similarity level appear to bind some of the same
compounds, potentially due to interaction with conserved
binding pocket amino acid residues among the protein
targets. Looking across the bioactivity results of such
related assays may help one to identify and separate
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checking assays with targets from the same biological
pathways (Figure 2b), shows that the protein targets of
AID 1751 and several related assays discussed above are
all involved in the Type II diabetes mellitus pathway as
annotated by the KEGG resource (23). Altogether, assay
neighboring relationships and the web-based summary
service provide the means to facilitate scientiﬁc discovery
by combining related information available within
PubChem and Entrez.
SEARCH, PUBLIC ACCESS AND DOWNLOAD
PubChem BioAssay can be searched using Entrez at
(http://www.ncbi.nlm.nih.gov/pcassay) or through the
PubChem web page at (http://pubchem.ncbi.nlm.nih.
gov) (Figure 1). Queries are made using particular terms
or keywords to locate and display matching assays. A
default search will match the term to all indexed ﬁelds.
For example, a search for ‘Parkinson’s disease’ ﬁnds 19
records that were contributed by diﬀerent laboratories
(Figure 3). Entrez provides a document summary
(DocSum) for each matching BioAssay record. This
includes the assay name, data source, target description
and links to all integrated resources. One can access the
full assay record using the ‘Summary’ link or retrieve
actual test results using the ‘Data’ link. In addition to
index searching, Entrez provides cross-links for each
assay record in the search results to related records in
other Entrez databases, found in link menus called
‘Related BioAssays’, ‘Chemicals’, ‘Target’, ‘Literature’
and ‘Other Links’ to the right of each search result.
Figure 2. (a and b) Tool for visualizing related bioassay relationships. One can examine the four types of derived bioassay neighboring relationships
for AID 1751 targeting human muscle isoform 2 pyruvate kinase using the provided ‘Target Similarity’, ‘Activity Overlap’, ‘Depositor’ and ‘Common
BioSystems’ tabs.
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‘Links’ line above the results list. These links include
related assays, active/inactive chemicals, molecular
targets, biosystems, PubMed articles, genes, taxonomy,
OMIM, etc. For example, one may ﬁnd out how many
targets have been tested among the 19 bioassay
experiments related to ‘Parkinson’s disease’ by clicking
the ‘Target|Protein Target’ link on the top of the page,
or one may retrieve the active compounds discovered by
the ‘JNK3 AlphaScreen Assay’ (AID 530) via the
‘Chemicals|PubChem Compound, Active’ link associated
with AID 530.
In Entrez, the scope of a search can be restricted to a
particular search ﬁeld (e.g. target name). To do this,
specify the name of the ﬁeld in brackets after the search
term. For example, to search for assays for the AKT1
target, one could enter ‘AKT1[ProteinTargetName]’.
Alternatively, search ﬁelds can be chosen from a
pulldown menu on the advanced search page found by
clicking on the ‘Limits’ tab in the DocSum view. The
‘Limits’ facility helps to build a query from a subset of
available search ﬁelds and ﬁlters (Figure 4). For example,
one can easily identify ‘Summary’ assays containing a
chemical probe report by selecting the ‘Summary, Probe’
option under the ‘BioAssay Type’ section and clicking
‘Go’ at the top of the page. Queries can also be built up
to reﬁne a search. For example, a query in PubChem
BioAssay of ‘aspirin AND ‘‘NIH Molecular Libraries
Program’’[SourceCategory]’ will retrieve all assays
deposited by the NIH-funded screening centers where
aspirin was tested. To keep things simpler for complex
searches, the ‘History’ tab can be used to combine
previous searches with Boolean logic. There is also a
‘Preview/Index’ tab to ﬁnd a detailed listing of all search
terms being indexed. A list of all search ﬁelds and
link ﬁlters are in the PubChem Help page
Figure 2. Continued.
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index). Documentation for general use of the NCBI
Entrez system is also available (http://www.ncbi.nlm.nih
.gov/Database/index.html).
One can directly access individual assay records through
the BioAssay Summary service by providing a valid
PubChem BioAssay accession (AID). A direct URL to a
given bioassay can easily be constructed, such as for assay
AID 123 (http://pubchem.ncbi.nlm.nih.gov/assay/assay
.cgi?aid=123). Similarly, direct URLs of summaries
for substance SID 123 (http://pubchem.ncbi.nlm.nih
.gov/summary/summary.cgi?sid=123) and compound
CID 123 (http://pubchem.ncbi.nlm.nih.gov/summary/
summary.cgi?cid=123) are easy to construct as well.
A bioassay summary for each assay record provides a
summary of all deposited assay information, including
descriptions, annotations and assay results (Figure 5).
It allows one to retrieve and download test results as well
as chemical structures of tested small molecules through
the ‘BioAssay Results|Data Table’ links. It also provides
a central entry point to begin an analysis of active
compounds using the bioactivity analysis tool through
the ‘BioActive Compounds|BioActivity Summary’ or
‘BioActive Compounds|Structure-Activity Analysis’ link.
It allows one to learn more about the target by following
the various annotations, to explore assay neighboring
relationships through the ‘Related BioAssays|Summary’
links or to review depositor-provided cross-references.
Figure 3. Search of the PubChem BioAssay database using the keywords ‘Parkinson’s disease’ returns, among others, a series of related assays
screening for the various targets associated with the disease process. Cross-links with other database records such as active compounds and protein
targets are available via the links pop-up menus at the top of the DocSum page for the entire search result list and are available via link menus on
the right side of each entry in the DocSum for the individual bioassay record.
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be downloaded via the PubChem FTP site (ftp://ftp.ncbi
.nlm.nih.gov/pubchem/Bioassay). PubChem BioAssay
descriptions and data are stored in ASN, XML and
CSV ﬁle formats. A concise view of the data consisting
of activity outcome, score and active concentration is
available under the ‘Concise’ directory. Pairwise lists of
related assays based on activity overlap, target similarity,
common biological pathway or depositor provided simi-
larity are available under the AssayNeighbors directory.
Data structure and ﬁelds contained within the FTP ﬁles
are modiﬁed when there is a schema change for the
BioAssay data speciﬁcation or a request for additional
ﬁelds to be dumped from the PubChem BioAssay
database. Cron jobs for dumping BioAssay FTP ﬁles
run weekly in full and daily in incremental modes. Assay
descriptions and data table can also be retrieved and
downloaded through a programmatic interface using the
PubChem PUG/SOAP facilities (http://pubchem.ncbi
.nlm.nih.gov/pug/pughelp.html).
BIOACTIVITY ANALYSIS TOOLS
When identifying a potential molecular probe or lead can-
didate against a given target, researchers need to examine
the biological activity results of a screening campaign.
Substances that are deemed active in a primary screen
are tested in subsequent conﬁrmatory and counter
screens, either repudiating or conﬁrming the value of the
initial positive test result. In PubChem, a substance is
often found to be tested in multiple biological assays
and screened against various targets; thereby, it is impor-
tant for researchers to aggregate and compare the assay
data to understand the biological activity proﬁle of a small
molecule of interest. Performing such analyses can be
laborious and time consuming without appropriate tools
to rapidly summarize biological tests.
To aid assay data analysis, PubChem provides a suite
of web-based bioactivity analysis tools allowing one
to download and search individual test results, compare
biological activity data from multiple screenings, examine
Figure 4. A screenshot for the BioAssay ‘Limits’ page. One can use this facility to retrieve bioassay records for a particular target using the ‘Target’
menu, to collect a list of bioassays records that have IC50 reported using the ‘Active Concentration|Speciﬁed’ option, to identify siRNA screening
experiments using the ‘BioAssay Type|Substance Type|RNAi’ feature, or to ﬁnd out assays targeting a speciﬁc protein by selecting one from the
‘Target’ menu.
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ships for compounds of interest. Part of the bioactivity
analysis tools can be accessed directly through links
provided at the PubChem web page at http://pubchem
.ncbi.nlm.nih.gov/ (Figure 1). Detailed descriptions
about the major components of the data analysis tools
and their integration with the rest of the NCBI informa-
tion system have been provided in a previous work (2).
CONCLUSION
PubChem BioAssay provides a comprehensive platform to
select and summarize the bioactivities of tested substances.
Additional tools support structure–activity analysis and
download of selected results. The PubChem BioAssay
system is continually reﬁned with incremental perfor-
mance and interface improvements and addition of new
components, tools and services. PubChem is designed to
serve as an archive for the large volume of screening data
generated by the NIH Molecular Libraries Program
(MLP), as well as for bioactivity information contri-
buted by the broader scientiﬁc community. One future
direction is to collect additional bioactivity results
from the research community by working with other
laboratories performing screening and medicinal chemis-
try research and with journal publishers and authors.
Other future directions include better integration with
additional information resources available at NCBI,
developing facilities to better analyze siRNA screening
results, providing better programmatic access to
PubChem BioAssay resources and better emphasis of the
bioactive chemical probe information generated by the
MLP. PubChem welcomes further contributions of
bioactivity results for tested substances, including
bioactivity results for both small molecules and siRNA
probes.
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